MA30597B1 - Utilisation d'une matrice hydrophile comportant un derive de l'acide polyacrylique, un ether de cellulose et un delitant pour la fabrication d'un medicament destine a traiter des troubles genitaux feminins - Google Patents

Utilisation d'une matrice hydrophile comportant un derive de l'acide polyacrylique, un ether de cellulose et un delitant pour la fabrication d'un medicament destine a traiter des troubles genitaux feminins

Info

Publication number
MA30597B1
MA30597B1 MA31583A MA31583A MA30597B1 MA 30597 B1 MA30597 B1 MA 30597B1 MA 31583 A MA31583 A MA 31583A MA 31583 A MA31583 A MA 31583A MA 30597 B1 MA30597 B1 MA 30597B1
Authority
MA
Morocco
Prior art keywords
polyacrylic acid
cellulose ether
medicament
manufacture
hydrophilic matrix
Prior art date
Application number
MA31583A
Other languages
English (en)
Inventor
Luigi Bruschi Stefano De
Federico Mailland
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of MA30597B1 publication Critical patent/MA30597B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UTILISATION D'UNE MATRICE HYDROPHILE COMPORTANT UN DÉRIVÉ DE L'ACIDE POLYACRYLIQUE, UN ÉTHER DE CELLULOSE ET UN DÉLITANT POUR LA FABRICATION D'UN MÉDICAMENT DESTINÉ À TRAITER DES TROUBLES GÉNITAUX FÉMININS Une matrice hydrophile est révélée qui comporte: a) au moins un dérivé de l'acide polyacrylique en quantité préférées de 0,5 à 40%, b) au moins un éther de cellulose en quantités préférées de 30 à 90 % et c) au moins un délitant en quantités préférées de 2 à 50 %, par rapport au poids de la matrice Cette matrice est utilisée conjointement avec au moins un principe actif acceptable pharmaceutiquement afin de fabriquer des formulations solides à libération contrôlée bioadhésives pour traiter des troubles vaginaux, tels qu'une candidose vulvovaginale, une vaginose bactérienne ou une trichomonase. Selon un mode de réalisation préféré, la matrice est utilisée en quantités de 5 à 60% environ et le principe actif en quantités de 2 à 70 % environ, par rapport au poids de la formulation.
MA31583A 2006-06-29 2009-01-22 Utilisation d'une matrice hydrophile comportant un derive de l'acide polyacrylique, un ether de cellulose et un delitant pour la fabrication d'un medicament destine a traiter des troubles genitaux feminins MA30597B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06116269A EP1872775A1 (fr) 2006-06-29 2006-06-29 Emploi d'une matrice hydrophile contenant un dérivé polyacrylique, un éther de cellulose et un désintégrant, pour la production d'un médicament pour le traitement des troubles génitales d'une femme

Publications (1)

Publication Number Publication Date
MA30597B1 true MA30597B1 (fr) 2009-07-01

Family

ID=37433668

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31583A MA30597B1 (fr) 2006-06-29 2009-01-22 Utilisation d'une matrice hydrophile comportant un derive de l'acide polyacrylique, un ether de cellulose et un delitant pour la fabrication d'un medicament destine a traiter des troubles genitaux feminins

Country Status (25)

Country Link
US (1) US8865201B2 (fr)
EP (2) EP1872775A1 (fr)
JP (1) JP5205374B2 (fr)
KR (1) KR101443149B1 (fr)
CN (2) CN101478951A (fr)
AR (1) AR061771A1 (fr)
AT (1) ATE455534T1 (fr)
BR (1) BRPI0713298A2 (fr)
CA (1) CA2652226C (fr)
CO (1) CO6140022A2 (fr)
CY (1) CY1109910T1 (fr)
DE (1) DE602007004486D1 (fr)
DK (1) DK2032123T3 (fr)
EA (1) EA018257B1 (fr)
ES (1) ES2339069T3 (fr)
HK (1) HK1128587A1 (fr)
HR (1) HRP20100159T1 (fr)
MA (1) MA30597B1 (fr)
MX (1) MX2008016508A (fr)
NO (1) NO20090095L (fr)
PL (1) PL2032123T3 (fr)
PT (1) PT2032123E (fr)
RS (1) RS51279B (fr)
SI (1) SI2032123T1 (fr)
WO (1) WO2008000683A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2344673B1 (es) 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
EP2163240A1 (fr) * 2008-09-12 2010-03-17 Universita' Degli Studi Di Genova Méthode pour la production des matrices compactes bioadhésives
JP5608167B2 (ja) * 2008-10-23 2014-10-15 ヘンケル コーポレイション 加工デンプンを含む医薬ペレット、およびそれの治療への応用
ES2344675B1 (es) * 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
EP2243482A1 (fr) * 2009-04-20 2010-10-27 Polichem SA Utilisation de nifuratel pour traiter des infections provoquées par des espèces d'Atopobium
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (fr) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Preparations et therapies de substitution pour hormonotherapie naturelle combinee
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
BR112016009008B8 (pt) * 2013-10-22 2023-01-31 Therapeuticsmd Inc Uso de estradiol e/ou hemi-hidrato de estradiol e de um agente solubilizante compreendendo um óleo de cadeia média para a preparação de um pessário para o tratamento de atrofia vulvovaginal e pessário que compreende estradiol
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN105796520A (zh) * 2014-12-29 2016-07-27 四川滇虹医药开发有限公司 一种缓释型硝酸布康唑直压片剂及其制备方法
US10716305B2 (en) 2015-01-23 2020-07-21 Biocidium Biopharmaceuticals Inc. Anti-bacterial compositions
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Compositions d'hormones stéroïdes dans des huiles à chaîne moyenne
CA3020153A1 (fr) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Composition pharmaceutique d'hormone steroide
US11026883B2 (en) * 2016-10-13 2021-06-08 Catalent U.K. Swindon Zydis Limited Lyophilized pharmaceutical compositions for vaginal delivery
GB201808567D0 (en) * 2018-05-24 2018-07-11 Douglas Pharmaceuticals Ltd Pharmaceutical compositions
CN109010320B (zh) * 2018-09-18 2021-09-14 浙江汇能生物股份有限公司 一种双释型聚卡波非钙颗粒剂及制备方法和畜禽中的应用
CN114129530A (zh) * 2021-12-08 2022-03-04 南京康川济医药科技有限公司 一种黄体酮缓释组合物及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2096744A (en) 1932-10-27 1937-10-26 Schering Corp Hydrogenation products of follicle hormones and method of producing same
US2232438A (en) 1934-08-04 1941-02-18 Schering Corp Unsaturated pregnanolones and pregnandiones and a method of producing the same
US2243887A (en) 1935-11-09 1941-06-03 Schering Corp Tertiary carbinols of the cyclopentano-polyhydrophenanthrene series and a method of producing the same
US2251939A (en) 1935-11-22 1941-08-12 Schering Corp Tertiary alcohols of the cyclopentano polyhydro phenanthrene series and a method of producing the same
US2379832A (en) 1936-06-02 1945-07-03 Schering Corp Process for the manufacture of unsaturated ketones of the cyclopentano polyhydro phenanthrene series
CH202847A (de) 1937-06-26 1939-02-15 Chem Ind Basel Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe.
US2265976A (en) 1937-10-25 1941-12-09 Schering Corp Tertiary alcohols of the estrane series and their derivatives and a process for their manufacture
US2314185A (en) 1939-09-01 1943-03-16 Zondek Bernhard Process for the manufacture of progesterone
BE665514A (fr) 1964-06-16
NL146838B (nl) 1966-06-24 1975-08-15 Organon Nv Werkwijze voor het bereiden van (delta)5(10)-3- keto-19-norsteroiden.
JPS5562012A (en) * 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US7744916B2 (en) * 1997-06-11 2010-06-29 Umd, Inc. Coated vaginal device for delivery of anti-migraine and anti-nausea drugs
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
UA74168C2 (uk) 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
EP1305021A4 (fr) 2000-06-23 2009-09-23 Teva Pharma Composition a expansion rapide pour retention gastrique et liberation regulee d'agents therapeutiques, et formes posologiques renfermant cette composition
FR2813865B1 (fr) 2000-09-08 2002-12-20 Rexam Sofab Dispositif a buse unique pour la distribution selective de deux produits
JP2004509142A (ja) 2000-09-19 2004-03-25 シーマ・ラブス・インコーポレイテッド 直腸及び膣投与用医薬組成物
JP4959907B2 (ja) * 2001-03-27 2012-06-27 ワーナー チルコット（アイルランド）リミティド 抗菌剤投与のための膣内用ドラッグデリバリーデバイス
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
CN1302764C (zh) 2005-01-10 2007-03-07 凌沛学 一种妇科用药阴道凝胶片

Also Published As

Publication number Publication date
CY1109910T1 (el) 2014-09-10
PT2032123E (pt) 2010-04-07
KR20090033341A (ko) 2009-04-02
JP2009541419A (ja) 2009-11-26
NO20090095L (no) 2009-01-07
US8865201B2 (en) 2014-10-21
EP2032123A1 (fr) 2009-03-11
CA2652226A1 (fr) 2008-01-03
CO6140022A2 (es) 2010-03-19
CN103071157A (zh) 2013-05-01
WO2008000683A1 (fr) 2008-01-03
EP1872775A1 (fr) 2008-01-02
US20110091555A1 (en) 2011-04-21
CN101478951A (zh) 2009-07-08
CA2652226C (fr) 2014-08-12
HRP20100159T1 (hr) 2010-05-31
EA200900087A1 (ru) 2009-06-30
ES2339069T3 (es) 2010-05-14
PL2032123T3 (pl) 2010-06-30
EA018257B1 (ru) 2013-06-28
ATE455534T1 (de) 2010-02-15
KR101443149B1 (ko) 2014-09-23
JP5205374B2 (ja) 2013-06-05
EP2032123B1 (fr) 2010-01-20
MX2008016508A (es) 2009-04-22
SI2032123T1 (sl) 2010-04-30
AR061771A1 (es) 2008-09-17
BRPI0713298A2 (pt) 2012-04-17
RS51279B (sr) 2010-12-31
DK2032123T3 (da) 2010-03-08
DE602007004486D1 (de) 2010-03-11
HK1128587A1 (en) 2009-10-30

Similar Documents

Publication Publication Date Title
MA30597B1 (fr) Utilisation d'une matrice hydrophile comportant un derive de l'acide polyacrylique, un ether de cellulose et un delitant pour la fabrication d'un medicament destine a traiter des troubles genitaux feminins
RU2469726C2 (ru) Композиции с контролируемым высвобождением на основе кортикостероидов для лечения ушных болезней
US8349882B2 (en) Pharmaceutical composition for external use
CA2330500A1 (fr) Compositions pharmaceutiques gelifiables
TNSN07478A1 (fr) Ingredient pharmaceutique actif du cannabinoide pour des formes de dosage ameliorees
US10314914B2 (en) Iodophor composition and methods of use
EP1997478A3 (fr) Formulations liquides pour la prévention et le traitement de maladies et troubles de la muqueuse
US20060286054A1 (en) Pharmaceutical compositions for the treatment of psoriasis
EP2395998A1 (fr) Association d' avermectines ou mylbemycines avec des récepteurs adrénergiques pour le traitement ou la prévention des affections dermatologiques
US20030211173A1 (en) Lubrication composition
MX2019004238A (es) Composiciones farmaceuticas liofilizadas para suministro vaginal.
CL2011000848A1 (es) Composicion de crema topica estable que comprende ozenoxacina y un excipiente farmaceuticamente adecuado y uso de la composicion para la erradicacion de infecciones nasofaringeas en portadores nasales asintomaticos, y para el tratamiento o prevencion de infecciones de la piel, del tracto genital, y enfermedades de transmision sexual.
WO2020212760A3 (fr) Composés et procédés pour le traitement de troubles oculaires
US20070264362A1 (en) Method and composition for treating ear inflammation caused by dry ear
US11266600B2 (en) Emulsions for the topical treatment of dermal and mucosal infections
US20160008276A1 (en) Compositions and methods for enhancing the efficacy of contraceptive microbicides
MA30527B1 (fr) Formes galeniques associant aliskirene et hydrochlorothiazide
US20060137684A1 (en) Compositions and methods of treating irritation and kit therefor
Powell Vaginal thrush: quality of life and treatments
US20210322505A1 (en) Composition for use in the prevention and/or treatment of the genitourinary mucosa
MA33804B1 (fr) Composition pharmaceutique pour le traitement des brûlures cutanées
RU2517061C1 (ru) Способ лечения мужского бесплодия, обусловленного аутоиммунными реакциями против сперматозоидов
Aitken et al. Bridging the gap between male and female fertility control; contraception-on-demand
EP2886117B1 (fr) Compositions topiques pour le traitement des infections avec Gardnerella vaginalis
MA50979B1 (fr) Application de totarol et composition pharmaceutique contenant du totarol